GLI1 and osteosarcoma: Abnormal activation of Gli1 in terminally-differentiated cells is a known oncogenic biomarker in multiple cancer subtypes such as leukaemia, basal cell carcinoma, medulloblastoma and osteosarcoma making it an ideal drug discovery target [71,72].